Back to mobile site

BTIG on Verastem (VSTM): data supports drug's ~$1B peak sales potential

April 10, 2026 12:26 PM EDT Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $19.00 price target on Verastem (NASDAQ: VSTM)The analyst commented, "Two-year follow-up ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login